82W Stock Overview Operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hims & Hers Health, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hims & Hers Health Historical stock prices Current Share Price US$25.78 52 Week High US$33.09 52 Week Low US$7.60 Beta 1.3 1 Month Change -17.58% 3 Month Change 57.77% 1 Year Change 236.55% 3 Year Change 409.49% 5 Year Change n/a Change since IPO 108.10%
Recent News & Updates
High number of new directors Dec 30
Hims & Hers Health, Inc. Announces Management Appointments Nov 19
Lead Independent Director recently sold €1.1m worth of stock Nov 15
Investor sentiment improves as stock rises 44% Nov 12
New minor risk - Insider selling Nov 08
Third quarter 2024 earnings released: EPS: US$0.35 (vs US$0.036 loss in 3Q 2023) Nov 06 See more updates
High number of new directors Dec 30
Hims & Hers Health, Inc. Announces Management Appointments Nov 19
Lead Independent Director recently sold €1.1m worth of stock Nov 15
Investor sentiment improves as stock rises 44% Nov 12
New minor risk - Insider selling Nov 08
Third quarter 2024 earnings released: EPS: US$0.35 (vs US$0.036 loss in 3Q 2023) Nov 06 Hims & Hers Health, Inc. Raises Financial Guidance for the Full Year 2024
Hims & Hers Health, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 15
Second quarter 2024 earnings released: EPS: US$0.062 (vs US$0.034 loss in 2Q 2023) Aug 06
Hims & Hers Health, Inc. Announces Appointment of Kåre Schultz to Board of Directors Jul 22
Hims & Hers Health, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
High number of new and inexperienced directors Jun 12
Insider recently bought €1.8m worth of stock May 23
Forecast breakeven date moved forward to 2024 May 20
Hims & Hers Health, Inc. Appoints Anja Manuel to its Board of Directors May 18 Hims & Hers Health, Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024
First quarter 2024 earnings released: EPS: US$0.052 (vs US$0.049 loss in 1Q 2023) May 07
Hims & Hers Health, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 16
Hims & Hers Appoints Christopher Payne as Newest Board Member Apr 03
Lead Independent Director recently sold €3.2m worth of stock Mar 03
Hims & Hers Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 Feb 28
Full year 2023 earnings released: US$0.11 loss per share (vs US$0.32 loss in FY 2022) Feb 27
Forecast breakeven date moved forward to 2024 Feb 27
Hims & Hers Names Dan Kenger as the Company’s First Chief Design Officer Feb 20
Hims & Hers Health, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 06 Hims & Hers Health, Inc. Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss
New minor risk - Shareholder dilution Nov 07
Third quarter 2023 earnings released: US$0.036 loss per share (vs US$0.092 loss in 3Q 2022) Nov 07
Hims & Hers Health, Inc. Provides Revenue Guidance for the Full Year 2023 Nov 07
Hims & Hers Health, Inc. Names Khobi Brooklyn as Chief Communications Officer Oct 20
Hims & Hers Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 17
Hims & Hers Health, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023 Aug 09
Second quarter 2023 earnings released: US$0.034 loss per share (vs US$0.096 loss in 2Q 2022) Aug 08
Hims & Hers Health, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
New major risk - Share price stability Jul 16
Hims & Hers Health, Inc. Unveils Innovative Line of Personalized Solutions Jun 14
Hims & Hers Health, Inc. Appoints Ambar Bhattacharyya to Directorate Jun 08 Hims & Hers Health, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023
Forecast breakeven date moved forward to 2024 May 10
First quarter 2023 earnings released: US$0.048 loss per share (vs US$0.08 loss in 1Q 2022) May 09
Chief Medical Officer recently sold €229k worth of stock Mar 05
Full year 2022 earnings released: US$0.32 loss per share (vs US$0.58 loss in FY 2021) Mar 01
Hims Launches Hard Mints – A Highly Treatment for Erectile Dysfunction Feb 08
Hims & Hers Health, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 07
Hims & Hers Health, Inc. Launches New Line of Volumizing Shampoos and Conditioners Jan 19
Forecast to breakeven in 2025 Dec 31
Hims & Hers Appoints Dr. Pat Carroll as Chief Medical Officer Dec 21
Hims & Hers Health, Inc Appoints Scott Knoer as Chief Pharmacy & Innovation Officer Dec 06
High number of new and inexperienced directors Nov 23
Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.08 loss in 3Q 2021) Nov 09
Hims & Hers Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 08
Hims & Hers Health, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 18
Hims & Hers Health, Inc. Appoints Brian O’Shaughnessy as First Chief Communications Officer Oct 13
Hims & Hers Launches New Android Apps Sep 07 Hims & Hers Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022
Second quarter 2022 earnings released: US$0.096 loss per share (vs US$0.048 loss in 2Q 2021) Aug 09
Hims & Hers Health, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 08
Lead Independent Director recently bought €187k worth of stock Jun 11
Hims & Hers Health, Inc. Announces Launch of 6 New Hers Wellness Essentials Supplements Jun 08
No longer forecast to breakeven May 11 Hims & Hers Health, Inc. Revises Earnings Guidance for the Full Year 2022
Hims & Hers Health, Inc., Annual General Meeting, Jun 02, 2022 May 02
High number of new and inexperienced directors Apr 28
Hims & Hers Health, Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 12
Hims & Hers Doubles Skincare Product Offerings with A Suite of New Products Mar 30
Principal Accounting Officer recently sold €69k worth of stock Mar 03
Hims & Hers Health, Inc. Appoints Amee Parekh as Senior Vice President of Human Resources Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
Hims & Hers Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 24
Hims & Hers Launches New Line of Mental Wellness Supplements, with More Options to Help Support Stress, Sleep and Lack of Focus Feb 08
Hims & Hers Health, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022 Feb 02
Hims & Hers Health, Inc. Introduces New Prescription Dermatology Offerings Increasing Support for Women Experiencing Common Yet Emotionally Distressing Hair Loss Jan 14
Co-Founder recently bought €426k worth of stock Dec 16
Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.074 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.045 loss per share (vs US$0.008 loss in 2Q 2020) Aug 12
Hims & Hers Health, Inc. Expands Mental Health Offerings to Include Individual Online Therapy Jul 03
Hims & Hers Health, Inc. (NYSE:HIMS) entered into a letter of interest to acquire Apostrophe, Inc. Jun 25
Hims & Hers Health, Inc. Expands Hair Growth Offerings with Launch of Minoxidil 5% Foam Jun 24
Hims & Hers Health, Inc. (NYSE:HIMS) agreed to acquire Honest Health Limited. Jun 15
Hims & Hers Now Offering a Dual-Action Topical Hair Loss Treatment for Men Jun 03
Hims & Hers Health, Inc. Partners with Alex Rodriguez to Launch Blur Stick Concealer May 21
First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.17 loss in 1Q 2020) May 21
Forecast to breakeven in 2024 May 18
Hims & Hers Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2021 May 18
Full year 2020 earnings released: US$0.23 loss per share (vs US$0.94 loss in FY 2019) Mar 20
Hims & Hers Health, Inc. Provides Earnings Guidance for the First Quarter 2021 and Full Year 2021 Mar 20
Hims & Hers Health, Inc Announces Board Changes Mar 12 Shareholder Returns 82W DE Healthcare DE Market 7D 1.1% 1.3% 2.0% 1Y 236.6% 19.9% 9.6%
See full shareholder returns
Return vs Market: 82W exceeded the German Market which returned 9.6% over the past year.
Price Volatility Is 82W's price volatile compared to industry and market? 82W volatility 82W Average Weekly Movement 18.1% Healthcare Industry Average Movement 4.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 82W's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 82W's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
Show more Hims & Hers Health, Inc. Fundamentals Summary How do Hims & Hers Health's earnings and revenue compare to its market cap? 82W fundamental statistics Market cap €5.86b Earnings (TTM ) €98.18m Revenue (TTM ) €1.20b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 82W income statement (TTM ) Revenue US$1.24b Cost of Revenue US$234.34m Gross Profit US$1.01b Other Expenses US$906.39m Earnings US$101.26m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 23:16 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hims & Hers Health, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Vikram Kesavabhotla Baird Allen Lutz BofA Global Research Michael Cherny BofA Global Research
Show 19 more analysts 
